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ABSTRACT
We identified Oligoribonuclease (Orn), an essential
Escherichia coli protein and the only exonuclease
degrading small ribonucleotides (5mer to 2mer) and
itshumanhomologue,smallfragmentnuclease(Sfn),
in a screen for proteins that are potentially regulated
by 30-phosphoadenosine 50-phosphate (pAp). We
show that both enzymes are sensitive to micromolar
amountsofpApinvitro.WealsodemonstratethatOrn
candegradeshortDNAoligosinadditiontoitsactivity
on RNA oligos, similar to what was documented for
Sfn. pAp was shown to accumulate as a result of
inhibition of the pAp-degrading enzyme by lithium,
widely used to treat bipolar disorder, thus its regula-
tory targets are of significant medical interest. CysQ,
the E.coli pAp-phosphatase is strongly inhibited by
lithium and calcium in vitro and is a main target of
lithium toxicity in vivo. Our findings point to remark-
able conservation of the connection between sulfur-
and RNA metabolism between E.coli and humans.
INTRODUCTION
While the basic building blocks of the cell are usually con-
sidered when studying intermediary metabolism, some are
overlooked. 30-phosphoadenosine 50-phosphate (pAp) in the
metabolism of sulfur is a case in point. It is a ubiquitous 30-
phosphorylated nucleotide derived from sulfur assimilation.
pAp is generated from phosphoadenosine 50-phosphosulfate
(PAPS), in an intermediate step in sulfate assimilation, by two
different mechanisms, as a by-product of either (i) sulfonation
reactions, or (ii) reduction to sulﬁte. Sulfonation, catalyzed by
numerous sulfotransferases is the transfer of sulfate to a large
number of acceptor molecules that play important roles in
mammalian cells; in addition to its effects on structure and
function of macromolecules, sulfonation is also involved in
deactivation and bioactivation of hormones, neurotransmit-
ters,xenobiotics and elimination ofend productsof catabolism
(1). Reduction of PAPS to sulﬁte is part of the pathway that
leads to the biosynthesis of cysteine or methionine in micro-
organisms, a pathway that is absent in humans.
Furthermore, and independent from sulfur metabolism, pAp
is also generated from coenzyme A during the transfer of the
4-phosphopantetheine group to acyl carrier protein (ACP) in
fattyacidsynthesisortosecondarymetabolitessuchaspeptide
antibiotics, surfactin or polyketides (2).
Regardless of how pAp is made, it needs to be recycled to
AMP, which is accomplished by a 30-nucleotidase. In
Escherichia coli, CysQ plays this role. Mutants in cysQ
require cysteine or sulﬁte for aerobic growth (3) and were
therefore originally suggested to help control the pool of
PAPS or a toxic derivative of it. Later the protein was
shown to hydrolyze pAp in vitro (4). The question arises
whether this nucleotide is solely a metabolic intermediate
or whether it has regulatory function as well. pAp is known
to act as competitive inhibitor of enzymes that use PAPS,
mainly PAPS reductase and sulfotransferases (1) and to inhibit
Xrn1p in yeast (5); however, other targets could also exist.
The importance of the search for pAp targets is attested by
the fact that the enzymes degrading pAp belong to a struc-
turally conserved protein family that is uniquely inhibited by
lithium (6). Lithium has been used for ﬁve decades to treat
bipolar disorder, a severe and often life-threatening disease.
Lithium proved to be an effective drug for this disorder and
shows prophylactic as well as therapeutic effects on both the
manic and the depressive phases, yet the molecular basis of its
action is still not understood.
The inhibition of pAp-phosphatase by lithium occurs via an
uncompetitive mechanism and is characterized by a low Ki of
0.3 mM (7). This value lies below the therapeutic concentra-
tion range (0.6–1.2 mM) and deﬁnes pAp-phosphatase as the
most sensitive lithium target described in the literature so far.
Physiological signiﬁcance of this inhibition is inferred from
*To whom correspondence should be addressed. Tel: +33 140613870; Fax: +33 145688948; Email: umechold@pasteur.fr
  The Author 2006. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
2364–2373 Nucleic Acids Research, 2006, Vol. 34, No. 8
doi:10.1093/nar/gkl247the demonstration of pAp accumulation to millimolar range in
yeast treated with lithium (8). Moreover, recent data show
direct evidence that it is this accumulation of pAp that medi-
ates the toxic effect of lithium in yeast (9). It is not known if
this correlation is evolutionary conserved and how pAp causes
toxicity. pAp could therefore account for some of the toxic
effects of lithium administration in humans treated for bipolar
disorder. In addition it could also account for some of the
therapeutic effects. For this reason, we were interested in
investigating regulatory targets of pAp, starting from the
model bacterium E.coli. Among the proteins identiﬁed are
the oligoribonuclease from E.coli and its human homolog
small fragment nuclease, both 30 and 50 exonucleases are
involved in the degradation of small single-stranded oligonu-
cleotides. Our ﬁndings, extending in an unexpected domain
the aphorism ‘what is true for E.coli is true for the elephant’,
show that at least one indirect target of lithium treatment is
remarkably evolutionarily conserved, suggesting that the role
of pAp is probably more important than previously suspected.
MATERIALS AND METHODS
Strains, plasmids, growth conditions
E.coli strains were grown at 30 C in MOPS-minimal medium
(10) containing 40 mg/ml of amino acids as indicated,
K-phosphate at 2 mM, vitamin B1 at 0.0005%, glycerol at
0.4%, glucose or arabinose as indicated. Ampicillin
(100 mg/ml) or kanamycin (25 mg/ml) was added for plasmid
maintenance or to select for chromosomal marker. CC118 (11)
was a gift from Elie Dassa. The plasmid for overexpression
of His-tagged Sfn, phyjeR-His was kindly provided by
David M. Wilson III and is described in Ref. (12).
Two CysQ deletion mutants were created following
the protocol of Yu et al. (13). Strain CF10230 was used for
mutagenesis. This strain was kindly supplied by Michael
Cashel and is a nic+ derivative of DY329 (M. Cashel,
unpublished data). The kanamycin resistance cassette was
PCR-ampliﬁed from FB8PPC::kan, a gift from Francis
Biville (F. Biville, unpublished data). Primer UM144,
50-GGGTATAAGTAAAACAATAAGTTAACACCGCT-
CACAGAGACGAGGTGGAGAAgccacgttgtgtctcaaaatctc-30
(capitalized letters indicate the homology region to the
E.coli chromosome); and UM146, 50-TTTAGGTTGGGAGA-
AATCAGGATGGCAGAATCAGGAAATACACTGTTTCT-
ccgtcccgtcaagtcagcgta-30 were used for PCR of a fragment
used to delete the cysQ open reading frame (ORF) completely
creating mutant 1. A PCR fragment ampliﬁed by UM145:
50-CTTGCACGGAATGCAGGCGATGCCATTATGCAGG-
TCTACGACGGGACGAAAgccacgttgtgtctcaaaatctc-30 and
UM146 was used to create a cysQ mutant that leaves the
ﬁrst 24 amino acids intact, designated as mutant 2. This region
coding for the N-terminal 24 amino acids was suggested to
contain a promoter for cpdB, which is transcribed in the oppo-
site direction of cysQ by one study (3) but not by another (14).
Both mutants behaved identically under all conditions tested
here. Mutants were veriﬁed by conﬁrmation of the 50 site of
integration into the chromosome by means of PCR using
primers UM147, 50-ACCGTCGCTGCATTCACACT-30; and
UM148, 50-TGCTTGATGGTCGGAAGAGG-30 yielding a
618 bp fragment for mutant 1 and a 690 bp fragment for
mutant 2, as well as the 30 site of integration using primer
UM149,50-AGACCGATACCAGGATCTTG-30;andUM150,
50-CTTATCCATGGCGTGAACAG-30 yielding a 656 bp
fragment for both mutants.
All experiments were performed in accordance with the
European regulation requirements concerning the use of
Genetically Modiﬁed Organisms (level 1 containment,
agreement no. 2735).
cysQ was cloned under control of the arabinose-inducible
promoter Para of pBAD18 by replacing the NheI/XhoI frag-
ment coding for RelSeq 1–224 from pUM131 leaving the
region coding for the C-terminal his-tag by a PCR fragment
containing the ORF for cysQ, ampliﬁed from MG1655 (15)
chromosomal DNA using primer UM133 (50-GGGGCTAG-
CAAGAAGGAGATATACCatgttagatcaagtatgccagcttgcac-30)
and UM131 (50-GGGGCTCGAGgtaaatagacactctgaaccccg-30)
yielding pUM404. Orn was cloned likewise using primer
UM143 (50-GGGGCTAGCAGGAGGAATTCACCatgagtgc-
caatgaaaacaacctgatttggat-30) and UM139 (50-GAGAGGTC-
GACcagcttgataaaatgctcgcggtagt-30) resulting in pUM408.
Chromosomal DNA for use as PCR template was prepared
using FTA cards (Whatman).
Purifiction of his-tagged CysQ, Orn and Sfn
CysQ and Orn were puriﬁed from 100 ml cultures, of MG1655
carrying the appropriate plasmid, grown at 30 Ct oa nA600
between 0.7 and 0.9, and then induced for 3 h with 0.2%
arabinose. Cells were harvested and washed once with
50 mM Na-phosphate, 300 mM NaCl before freezing. Frozen
pellets were resuspended in 1.5 ml binding buffer [50 mM
Na-phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole and
0.4 mM phenylmethylsulfonyl ﬂuoride (PMSF)] and lysed by
incubation on ice for 30 min with 130 mg/ml lysozyme fol-
lowed by sonication. After removal of cell debris by centrifu-
gation at 14 000 r.p.m. for 30 min, proteins were batch puriﬁed
on 500 ml Ni-agarose (Quiagen) according to the manufac-
turer’s instructions. Wash buffer contained 20 mM imidazole.
Elution wasdoneusingfouraliquotsof500mlofelutionbuffer
(same as binding buffer, but containing 250 mM imidazole).
The most pure fraction was identiﬁed by SDS–PAA gel elec-
trophoresis, dialyzed against 50 mM HEPES, pH 7.5 and 100
mM NaCl and kept on ice for storage. For puriﬁcation of Sfn,
the protocol needed to be adjusted due to the lower expression
level of this protein. Higher culture volume (400 ml instead of
100 ml) and less Ni-agarose 300 ml instead of 500 ml were
used. Induction was done by adding 1 mM isopropyl-b-D-
thiogalactopyranoside for 2 h 45 min before harvesting the
cells. Binding was done in the presence of 5 mM imidazole
instead of 10 mM.
pAp-agarose binding
Cyanogen bromide activated agarose beads (Sigma–Aldrich)
were blocked with 0.2 M glycine according to the instructions
of the supplier and stored at 4 C in 1M NaCl containing 0.02%
sodium azide. pAp-agarose (Sigma–Aldrich) was stored like-
wise after swelling and washing in H2O as indicated in the
protocol of the manufacturer. Before use, agarose beads were
washed three times with at least 10 vol of pAp-agarose buffer
[as in (4), 50 mM HEPES, pH 7.5, 10 mM CaCl2 and 50 mM
KCl). Cultures of CC118 (200 ml) were grown at 30 Ct oa n
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all amino acids but cysteine and methionine and 2% glucose,
harvested and washed once in 50 mM Na-phosphate pH 8.0,
300mMNaCl beforefreezing.Frozenpellets wereresuspended
in 2 ml pAp-agarose buffer containing 0.4 mM PMSF and lysed
as described above. Debris-free cellular extract was added to
200 ml blocked agarose beads and rotated for 2h at 4 Ct oc l e a r
the extract from proteins binding non-speciﬁcally to agarose.
Supernatant was divided equally and added to 50 mlo fw a s h e d
pAp-agarose (pAp-binding fraction) or blocked agarose beads
(control). After rotation at 4 C for 1 h 30 min, the beads were
washed extensively (10 times 800 ml) with pAp-agarose wash
buffer (as pAp-agarose buffer but 0.5 M NaCl), and washed
once with pAp-agarose buffer to remove excessive salt. Elution
w a sd o n eb ya d d i n g7 5ml of hot SDS-sample buffer, and
incubation at 65 C for 15 min. Beads were removed by cen-
trifugation, and 20 ml of each sample was analyzed by gel
electrophoresis on 12% SDS–PAA gels. Bands corresponding
to proteins binding speciﬁcally to pAp were localized by stain-
ing with Bio-Safe colloidal coomassie (Bio-Rad), cut out and
digested in-gel by trypsin after reduction and alkylation accor-
ding to standard protocols and analyzed by nano-HPLC (LC
Packing) directly coupled to an ion trap mass spectro-
meter (ThermoFinnigan LCQ Deca XP) equipped with a nano-
electrospray source (LC-MS/MS). Database searches and
evaluation of the results was done using the Bioworks 3.1
software. Overall scores were obtained using a multiple thresh-
oldﬁlterforindividualpeptides:1.5foronecharge,2fordoubly
charged and 2.5 for triply charged ions.
For pAp-binding experiments with human cells, HeLa cells
were grown in spinner ﬂasks in DMEM including 7% of fetal
bovine serum. Hundred million cells were used to prepare
cytoplasmic extract according to Dignam (16).
Orn/Sfn activity assay
Custom-made RNA or DNA oligo 5mers (50Cy5-CCCCC30),
obtained from Proligo or Sigma-Genosys, respectively, were
used as substrate for in-vitro activity assays. An aliquot of
30 ml reactions containing 50 mM HEPES, pH 7.5, 5 mM
MnCl2,3mM substrate and Orn or Sfn as indicated were
incubated at 37 C, and reactions were initiated by adding
substrate or by adding enzyme. Inhibitors were added as indi-
cated in the text. At intervals, 4.5 ml reaction aliquots were
taken and stopped by adding an equal volume of sample buffer
(4· TBE, 100 mM DTT, 16% glycerol and 20 mM EDTA) and
frozen at  20 C. For analysis of the reaction products, 1.5 or
2.5 ml of samples were applied to PAGE on a 22% SDS–PAA
gel containing 2· TBE and run in 2· TBE. Fluorescent RNA
oligos were visualized using a Molecular Dynamics STORM
860 in 650 nm long-pass ﬁlter mode. Quantiﬁcation of the data
was done by deﬁning the total amount of ﬂuorescence mea-
sured in the substrate (5mer) and the reaction products (4mer,
3mer, 2mer, 1mer) for each time point 100% and expressing
the amount of each reaction product as fraction of the total.
CysQ activity assay
CysQ activity was tested in 30 ml reactions containing 50 mM
HEPES,pH 7.5, 50 mM KCl, 200 mM NaCl, 2mM MgCl2and
5.5 mM pAp at 37 C, reactions were started by the addition of
0.5 mg CysQ. Inhibitors were added as indicated. At intervals,
4.5 ml samples were mixed with 0.5 ml of 100 mM EDTA, and
resolved by polyethyleneimine (PEI) thin-layer chromato-
graphy with 0.8 M LiCl as solvent. Authentic AMP and
pAp were used as migration standards. Accumulation of
reaction products was estimated after visualization by UV.
RESULTS
Identification of E.coli proteins binding to pAp, CysQ
and Orn
As a starting point to explore the regulatory function of pAp,
we chose the identiﬁcation of proteins interacting with this
nucleotide, namely pAp-afﬁnity chromatography. We chose to
do initial experiments on extracts of E.coli for two reasons:
(i) we were interested to learn if potential regulatory mecha-
nisms involving pAp could be evolutionary conserved and
(ii) experiments are easier to set up using bacterial extracts.
We used E.coli CC118, a strain harboring a deletion, for alka-
line phosphatase in order to prevent degradation of the afﬁnity
substrate. CaCl2 was included in the buffer for binding in the
anticipation that it can prevent degradation of pAp by pAp-
phosphatase as pAp-phosphatases were shown to be sensitive
to CaCl2 (17–19). In addition, these conditions had been pro-
ven useful for the puriﬁcation of the human pAp-phosphatase,
BPNT1(4).
Three major protein bands became visible in the fraction of
protein binding speciﬁcally to pAp (Figure 1). Analysis of
these bands by LC-MS/MS or direct sequencing revealed
CysQ (SwissProt, P22255) for band number 1, HisIE
(SwissProt, P06989) for band number 2, and oligoribo-
nuclease, Orn (SwissProt, P39287) for band number 3.
CysQ was identiﬁed with an overall score of 860 repre-
sented by ﬁve distinct peptides, covering 22.3% of the total
mass of the protein. Orn was identiﬁed with an overall score
of 768, eight peptides covering 42% of the total protein mass
Figure 1. pAp-binding proteins from E.coli. Shown is colloidal coomassie
stained SDS–PAA gel separating the pAp-binding fraction of E.coli extract.
M, marker; lane 1, fraction binding to blocked agarose beads (control); lane 2,
pAp-binding fraction.
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following tryptic peptide, VGEEGVETAL.
The experiments described in the next part were intended to
characterize two of the proteins binding to pAp, CysQ and Orn
and in particular the consequences of their interaction with
pAp. The characterization of HisIE and the potential biologi-
cal consequencesofthe interactionofthisprotein withpApare
not objects of this study.
CysQ is a main target for lithium toxicity in E.coli
Like its homolog in yeast, Hal2 (20) and the mammalian
counterparts (BPNT1) (4,19), CysQ was shown to degrade
pAp to AMP (4). The identiﬁcation of CysQ as a protein
binding to pAp was therefore expected. Recovery of this pro-
tein shows that cross-linking to the matrix does not interfere
with major features of pAp as a substrate for speciﬁc
interactions.
CysQ carries a conserved sequence motif, D(X)n
EE(X)nDP(I/L)D(S/G/A)T(X)nWD(X)11GG required for
metal ion coordination that places it into a larger family of
magnesium-dependent phosphomonoesterases with otherwise
low overall sequence similarity but a conserved 3D core struc-
ture (6). Members of this family are predicted to be highly
sensitive to lithium, but this requires experimental substantia-
tion. To our knowledge, sensitivity of CysQ to lithium and
other salts was not tested before. We therefore decided to test
lithium sensitivity of CysQ using a his-tagged protein that was
puriﬁed to homogeneity. The his-tagged CysQ was shown to
be biologically functional by demonstrating its ability to com-
plement the phenotype of a cysQ deletion, namely a growth
defect in the absence of cysteine, when overexpressed under
the control of the arabinose-inducible promoter PBAD in
pBAD18 (Table 2).
As expected, CysQ-catalyzed pAp hydrolysis requires Mg
2+
(data not shown). Sensitivity to calcium was reported for pAp
phosphatases. For this reason CaCl2 was included in the test.
Figure 2 shows complete inhibition of CysQ in the presence of
either 1 mM LiCl or 2 mM CaCl2. Reactions were performed
inthe presence of 200mM NaCl. UndertheseconditionsCysQ
activity was higher than in the absence of NaCl. Thus, sodium
is not inhibitory at physiological concentrations and does not
interfere with lithium. Importantly, this places CysQ in the
class of sodium tolerant pAp phosphatases, together with
mammalian rat BPNT1 (19) and human BPNT1 (7) and
two homologous proteins in Arabidopsis, Sal1 and Sal2
(18), and contrasts it with the yeast proteins Hal2 (8) and
Tol1 (21) and the third pAp-phosphatase in Arabidopsis,
AHL (18).
As mentioned in the introduction, recent data show that
pAp-phosphatase Hal2p is a main target of lithium toxicity
in yeast. The observed sensitivity to lithium raises the possi-
bility that similarly, CysQ might be the main target of lithium
toxicity in E.coli. Evolutionary conservation of targets of sen-
sitivity to lithium between different domains of life is intri-
guing in light of the existence of conservation of regulatory
pathways in general and the interest in the molecular mecha-
nisms of lithium action in particular. To test this hypothesis,
the wild-type strain MG1655 was grown in the presence of
sulfate as sole sulfur source. Under these conditions, cysteine
needs tobesynthesized throughthe assimilation ofsulfate,and
pAp is produced as a by-product. Adding LiCl should inhibit
pAp-phosphatase and lead to an accumulation of pAp. A con-
siderable inhibitory effect of lithium on cell growth was
observed. Obvious differences in colony size were detected
already after plating cells in the presence of 50 mM LiCl (data
not shown). Severe growth inhibition was observed at 100 mM
LiCl (Figure 3, upper panel). Importantly, this growth defect
could be almost completely rescued by overexpression of
CysQ (Figure 3, lower panel). Similar experiments were
done in liquid medium. Addition of increasing amounts of
LiCl showed increasing inhibition of growth (Table 1). As
observed when growing on plates, overexpression of CysQ
rescues the growth defect completely. It can therefore be con-
cluded that CysQ is a main target for Li-toxicity under the
conditions used. Thus, it is very probable that as in yeast
additional direct targets for lithium toxicity do not exist.
For further conﬁrmation of this conclusion it would be inter-
esting to test if additional suppressors of lithium toxicity can
be identiﬁed from a multicopy library.
Orn is a potential downstream target of pAp
As lithium-toxicity is caused mainly by accumulation of pAp,
the question arises what are the downstream targets of pAp
accumulation. We expected that potential targets should be
found among the proteins binding to pAp, and identiﬁed Orn
as one of these proteins.
Orn is an essential protein in E.coli involved in mRNA
degradation. It has 30–50 exoribonuclease activity selectively
Table 1. Rescue of Lithium toxicity by overexpression of CysQ but not Orn
Plasmid Doubling time (min) for growth in the presence of
0 mM LiCl 100 mM LiCl 200 mM LiCl
pBAD18 (vector) 84 101 114
pUM404 (CysQ-His) 87 84 85
pUM408 (Orn-His) 92 104 120
Strain CF10230 carrying plasmids as indicated was grown in MOPS-minimal
mediumcontainingallaminoacidsbutcysteine,glycerolat0.4%andarabinose
at0.02%forinductionofPara.LiClwasaddedasindicatedatanOD600of 0.1,
and doubling times were measured thereafter.
Figure 2. Inhibition of recombinant CysQ by Lithium (1 mM) and Calcium
(2 mM). Reactions contained 5.5 mM pAp and 0.5 mg of CysQ. Closed circles,
no inhibitor; gray circles, LiCl; open squares, CaCl2.
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afﬁnity of Orn for pAp, we asked ﬁrst if pAp is a possible
substrate for Orn. Reactions were done as described for
Figure 2 for CysQ except that twice the amount of enzyme
was used (1 mg instead of 0.5 mg). CysQ served as positive
control. Under these conditions, all pAp was converted into
AMP after 5 min by CysQ. Orn was tested in the presence of
Mg2+ and Mn2+ at 2 mM. No conversion of pAp into AMP
was observed during 30 min (data not shown). pAp is therefore
not a substrate for Orn under the conditions tested.
Next we wanted to investigate if pAp has an effect on Orn
activity in vitro. Orn was shown to be most active on single-
stranded RNA oligonucleotides of  5 nt in length (23,24).
RNA oligo 5mers (50-CCCCC-30) labeled at their 50-phosphate
end with the sulfoindocyanine succinimidyl ester cyanine 5
(Cy5) were therefore used as substrate for in vitro assays with
puriﬁed recombinant Orn. Separating reaction products on
a 22% SDS–PAA gel, we observed a reverse migration
phenomenon. This effect can be accounted for by the fact
that cyanine dyes have a lower net negative charge than
nucleic acids; thus, removing nucleotides will reduce the
charge relative to the mass of the oligonucleotide and cause
it to shift up instead of down.
The sequential appearance of reaction products of different
chain length (Figure 4) is in agreement with previous data (24)
and the proposed processive reaction mechanism of oligori-
bonuclease. We tested Orn activity in the presence of different
concentrations of pAp (10, 20 and 50 mM). Increasing inhibi-
tion can be seen with increasing concentrations of pAp. We
chose to present here the kinetics of oligo-RNA degradation in
the presence of 20 mM pAp together with the control lacking
the inhibitor as this concentration of pAp causes a strong and
easily observable effect.
Preliminary results regarding salt sensitivity of Orn show
no sensitivity to LiCl up to 300 mM, and slight inhibition
by NaCl and CaCl2 starting from concentrations exceeding
100 mM with NaCl being more inhibitory than CaCl2
(data not shown).
Overexpression of orn cannot rescue the cysQ mutant
phenotype or the lithium effect on growth
Given the observed strong inhibition of Orn by pAp together
with the fact that Orn is essential in E.coli, we asked if the
cysQ mutant phenotype could be rescued by overexpressing
Orn. For this purpose growth tests were performed on MOPS-
minimal plates or in liquid medium. As shown in Table 2,
overexpression of Orn could not rescue the growth inhibition
seen in both cysQ mutants grown in the absence of Cysteine.
Also, Orn overexpression could not rescue the growth
inhibitory effect of lithium in the wild-type strain (Tables 1
and 2). As mentioned earlier, both effects can however be
rescued by cysQ overexpression. This raises the possibility
that additional downstream targets of pAp accumulation
exist in E.coli. Alternative explanations are discussed below.
Identification of pAp-binding proteins in human cells
The possibility that pAp accumulation caused by
lithium-inhibition of pAp-phosphatase may explain some of
the effects of lithium, either toxic or therapeutic, prompted
us to extend our search for pAp-binding proteins to
human cells. Cytoplasmicextracts of HeLa cells were dialyzed
against pAp-agarose buffer and concentrated (10-fold)
before binding experiments were performed in a similar
way as described for bacterial extracts. Figure 5 shows the
presence of three major proteins that bind speciﬁcally to pAp.
Identiﬁcation of band number 2 by LC/MS-MS revealed
nucleoside diphosphate kinase (NDK) with an overall score
of 280, 6 peptides covering 35% of the total mass:
DRPFFAGLVK, FMQASEDLLK, GDFCIQVGR, GLVEIIK,
NIIHCSDSVESAEK and TFIAIKPDGVQR.
Band number 3 was also identiﬁed as NDK with an overall
score of 158, and 4 peptides covering 16% of the total mass:
TFIAIKPDGVQR, PDGVQR, which is contained in peptide 1
and the result of a more complete trypsin digestion,
GDFCIQVGR and GLVEIIK.
NDK exists in different isoforms and different functions
have been reported for individual isoforms (Discussion).
The peptides identiﬁed for bands number 2 and number 3
do not allow distinguishing unequivocally between these
isoforms, differences in the molecular mass weight however
point to NDK A (SwissProt, P15531) for band number 3
with a predicted molecular mass weight of 17.1 kDa and a
transcriptional variant of the same gene (Uniprot, Q86XQ2)
(26) for band number 2 (19.6 kDa).
NDK was reported to be inhibited by 30-phosphorylated
nucleotides in vitro, in particular by pAp and PAPS (27).
Therefore, further validation of this ﬁnding was not pursued.
A downstream target of pAp accumulation is conserved
between E.coli and humans: Sfn
Identiﬁcation of band number 1 revealed small fragment
nuclease (Sfn) with an overall score of 338, and 7 peptides
covering 31% of the total mass. Sfn is the human homolog of
E.coliOrn andsharesahighdegreeofsimilarity (50%)with its
bacterialcounterpart(28).SfnandOrnbelongtoalargefamily
of 30–50 exonucleases that are characterized by three ancient
Figure 3. Lithium induced growth inhibition in E.coli MG1655 containing
pBAD18(vectorcontrol)orpUM404(arabinose-induciblecysQ).Strainswere
grown on MOPS-minimal plates containing all amino acids but cysteine and
methionine, 0.4% glycerol and 0.0002% arabinose.
2368 Nucleic Acids Research, 2006, Vol. 34, No. 8conserved exonuclease motifs (exo I, II and III) (29,30). As
does Orn, Sfn speciﬁcally degrades short oligoribonucleotides
of  5 nt in length. In addition, Sfn was shown to be active on
small DNA oligos (12). A role of Sfn in cellular nucleotide
recycling was therefore suggested. We puriﬁed his-tagged Sfn
in order to assess its sensitivity to pAp in vitro. As compared
with Orn, 7-fold more Sfn was necessary to obtain comparable
activity. The reason for this might lie in the fact that the human
enzyme was expressed in E.coli, which differ from mamma-
lian cells in folding and posttranslational modiﬁcation mecha-
nisms. Inhibition was tested at two concentrations of the
inhibitor, 20 and 50 mM. As shown in Figure 6, signiﬁcant
inhibition could be seen in the presence of 20 mM pAp, and
increasing inhibition was observed at 50 mM.
Initial experiments to test sensitivity of Sfn-catalyzed DNA
oligo degradation showed that pAp inhibits this activity of Sfn
as well (data not shown).
The recognition of Sfn as a pAp-regulated enzyme demon-
strates that at least one target of pAp accumulation is con-
served between E.coli and humans.
Orn is active on DNA oligos
Both Orn and Sfn belong to the 30–50 exonuclease superfamily,
which includes proofreading domains of all known DNA-
dependent DNA polymerases (28). Therefore Orn might be
abletodegrade shortDNAoligosaswell,apossibilitythatwas
never tested when this enzyme was characterized as a ribonu-
clease, since only double-stranded T7 DNA was used as a
DNA substrate (23). Figure 7 shows Orn activity on Cy5-
labeled oligo-DNA. 10-fold higher enzyme concentrations
were necessary to obtain degradation of DNA oligos as
compared with RNA oligos. Similar preferential degradation
of RNA over DNA had been shown for Sfn (12).
DISCUSSION
The purpose of this study was to explore the regulatory func-
tion of the nucleotide, pAp that is generated in both prokary-
otes and eukaryotes in the process of sulfur assimilation. In
addition to our interest in possible parallels of regulatory path-
ways between these two domains of life, pAp is of particular
interest for its possible involvement in the molecular effect of
lithium in the treatment of bipolar disorder. The beneﬁcial
effect of lithium on patients with bipolar disorder was
described for the ﬁrst time >50 years ago (31). Efforts to
identify targets of lithium concentrated to a large extent on
its action on glycogen synthase kinase (GSK)-3 (32,33) and
inositol monophosphatase (34,35). Those and other hypothe-
ses are reviewed (36,37). We focus here on lithium’s action on
members of a structurally conserved family of metal depen-
dent phosphomonoesterases that include inositol monophos-
phatase (6) and more particular on pAp-phosphatase, as the Ki
for lithium-inhibition of the human homolog with 0.3 mM (7)
is the lowest Ki described for lithium-inhibited enzymes. pAp
accumulation due to the inhibition of pAp-phosphatase could
explain some of the effect of lithium treatment. Our search for
regulatory targets of pAp was carried out in E.coli and in
human cells and started by the identiﬁcation of proteins bind-
ing to pAp followed by the attempt to understand the biologi-
cal consequences of the interaction of pAp with some of these
proteins. Among the proteins binding to pAp, we expected to
ﬁnd proteins that have pAp as a substrate or proteins that are
regulatedby pAp. In CysQ from E.coli,we found aprotein that
uses pAp as substrate and cleaves the 30 phosphate, leaving
AMP as a metabolite directly recycled in metabolism by
adenylate kinase. We demonstrate that CysQ, like other
members of a structurally conserved protein family, is highly
sensitive to lithium and calcium in vitro. Furthermore, CysQ is
not inhibited by physiological concentrations of sodium like
mammalian pAp-phosphatases, rat BPNT1 (19) and human
BPNT1 (SwissProt, O95861) (7) and two out of three homo-
logous proteins in Arabidopsis (Sal1 and Sal2) (18) and unlike
the yeast proteins Hal2 (P32179) (8) and Tol1 (21) and a third
homolog form Arabidopsis, AHL (18).
Interestingly, CysQ is a main target of lithium-toxicity in
E.coli as overexpression of this protein can rescue the growth
defect observed when bacterial cells are treated with LiCl. A
similar effect was observed in yeast (9). These authors demon-
strated a direct correlation between growth inhibition and pAp
levels when levels were manipulated either by genetics or
pharmacological adjustment. The evolutionary conservation
Figure 4. Orn is sensitive to micromolar amounts of pAp. Shown is the quan-
tification of the distribution of reaction products that were separated on 22%
PAA gels. Reactions included 0.07 mg Orn and 3 mM of RNA oligo 5mer
(50Cy5-CCCCC30). Reactions were started by the addition of substrate. pAp
(20 mM) was present where indicated. Closed circle, 5mer; open circle, 4mer;
closed triangle, 3mer; open triangle, 2mer; square, 1mer.
Nucleic Acids Research, 2006, Vol. 34, No. 8 2369of targets of sensitivity to lithium between different domains
of life is intriguing as it points to conservation of regulatory
pathways.
As an example for proteins regulated by pAp, we found
oligoribonuclease, Orn from E.coli. We show that this protein
is inhibited by micromolar amounts of pAp in vitro. Orn was
tested previously for inhibition by 50-o r3 0-mononucleotides
(24). That work found that 30 ribonucleotides did not have an
effect on Orn activity, whereas 1 mM of 50 ribonucleotides
(a concentration that is much higher than what we used in our
assays for pAp) inhibited Orn activity to various extents,
depending upon the particular nucleotide: GMP and AMP
were more inhibitory than UMP and CMP. 50-Ribonucleotides
are the end products of Orn reaction and they are therefore
expected to contribute to modulation of Orn activity. The
levels of mononucleotides in the cell are estimated to be
lower than 100 mM (38). The observed toxicity of LiCl treat-
ment in E.coli suggests that, as in the case of yeast (8,9),
pAp accumulates to considerably higher amounts than
ribomononucleotides.
Remarkably, when using HeLa cell extract, we found the
human homolog of Orn, Sfn to bind to pAp-agarose. In vitro
assays with his-tagged Sfn show that like Orn, Sfn is highly
sensitive to pAp. Orn and Sfn share a distinct substrate pref-
erence for oligoribonucleotides shorter than 5 nt in vitro.I n
E.coli, Orn is the only exoribonuclease that is able to degrade
small oligoribonucleotides (39), and short oligoribonu-
cleotides (2–5 nt) were shown to accumulate under circum-
stances of a conditional knockout (22). Orn is encoded by an
essential gene, which is unusual for E.coli exoribonucleases.
Ghosh and Deutscher (22) consider three different explana-
tions why the absence of Orn activity leads to cessation of
growth: (i) depletion of the cells’ mononucleotide pool, (ii)
inhibition of certain enzymes of essential metabolic processes
by accumulated oligoribonucleotides, or (iii) a yet unknown
function of Orn that is essential.
The human Orn homolog (Sfn) was shown to degrade small
DNA oligos in addition to oligoribonucleotides (12). These
short DNA oligos couldemerge from DNA repair and recomb-
ination and indeed it was shown that Sfn plays a role in
resistance to UV-C (40). Both Orn and Sfn belong to the
30–50 exonuclease superfamily, which includes proofreading
domains of all known DNA-dependent DNA polymerases
(28): we therefore decided to test the possibility that Orn
might be able to degrade short DNA oligos as well. We
show that, as for Sfn (12), DNA directed exonuclease activity
of Orn exists but requires higher enzyme concentrations than
RNA directed activity. Thus, as for Sfn, Orn could play a
possible role in DNA repair. Owing to the conservation of
the active center of exonucleolytic activity within the super-
family (29,30) one might wonder if the pAp-exerted inhibition
extends to other members as well. Notably, some of the mem-
bers of this superfamily were linked to human diseases like
Werner syndrome and polymyositis-scleroderma overlap syn-
drome 100 kDa autoantigen (41,42).
It is noteworthy that the effect reported here of pAp on RNA
degradation is not the ﬁrst example for the connection between
sulfur and RNA metabolism. In fact, inhibitory effects of pAp
on exonucleases Xrnp1 and Rat1p, two enzymes homolo-
gously conserved throughout eukaryotes [reviewed in (43)],
were reported before (5). Xrnp1 and Rat1p are required for
correct 50 processing of 5.8S RNA and snoRNA, degradation
of pre-RNA spacer fragments and mRNA turnover (5). Sta-
bilization of mRNA and subsequent changes in expression
patterns as well as additional changes in RNA metabolism
due to pAp-mediated inhibition of Xrn1p and Rat1p were
Table 2. Overexpression of orn cannot rescue the cysQ Mutant phenotype or the toxicity effect of Lithium
Strain cysQ allele Plasmid Growth on MOPS Minimal
+Cys  Cys  Cys, +LiCl
UM304 Wild type pBAD18 (vector) ++  
UM305 Wild type pUM404 (Para:cysQ-His) ++ +
UM306 Wild type pUM408 (Para:orn-His) ++  
UM307 Mutant 1 pBAD18 (vector) +   
UM308 Mutant 1 pUM404 (Para:cysQ-His) ++ +
UM309 Mutant 1 pUM408 (Para:orn-His) +   
UM310 Mutant 2 pBAD18 (vector) +   
UM311 Mutant 2 pUM404 (Para:cysQ-His) ++ +
UM312 Mutant 2 pUM408 (Para:orn-His) +   
BacteriaweregrownonplatesorinliquidcultureofMOPS-minimalmediumcontainingallaminoacidsorlackingcysteine.LiClwaspresentat100mMinplatesand
at 100 or 200 mM in liquid culture. Arabinose was present at 0.02% for induction of Para. Plus indicates normal growth, and minus indicates inhibited growth.
Figure 5. pAp-binding proteins from humans. Shown is colloidal coomassie
stained SDS–PAA gel separating the pAp-binding fraction of HeLa cytoplas-
mic extract. M, marker; lane 1, control; lane 2, pAp-binding fraction.
2370 Nucleic Acids Research, 2006, Vol. 34, No. 8proposed to account for developmental effects observed under
lithium treatment. More recent results on the Xrn1p homolog
from Arabidopsis point to speciﬁc mRNA targets for this
enzyme and to its involvement in miRNA mediated cleavage
(44).
Xrnp1 and Rat1p speciﬁcities are directed oppositely from
oligoribonucleases, namely from 50 to 30. To our knowledge,
ourstudyreportsfortheﬁrsttimeanexonucleasedirectedfrom
30 to 50 to be inhibited by pAp. In fact in yeast, 30–50 directed
degradationofmRNAwasshowntobeunaffectedbypAp(45).
The recurring ﬁnding of a connection between pAp and RNA
metabolism is of interest in light of the effect of RNA stability
on gene expression. In the case of Xrn1P, complex changes of
expression pattern were shown in mutants lacking this protein
(46).Similarly,pAp-mediatedinhibitionofoligoribonucleases
might have effects on gene expression. Ubiquitous expression
of Sfn points to an important role of this protein in mammals
(12).Intheabsenceofacompleteunderstandingoftherolethat
oligoribonucleases and in particular Sfn play, we can only
speculate about the possible consequences of their inhibition.
In this respect, it is interesting that Orn activity was shown to
displaysomedegreeofsequencespeciﬁcity(24),andtherefore,
its function could be targeted to a more speciﬁc set of short
oligoribonucleotides.TheroleofsmallRNAs,microRNAsand
siRNAsinhigherorganismsaswellassmallnon-codingRNAs
in bacteria in the regulation of gene expression is increasingly
recognized and has seen enormous advances in the last decade
[for reviews see (47–52)]. It is conceivable that short oligos
could interfere with the metabolism of those small RNAs by
means of hybridization and thereby contribute to changes in
gene expression. A recent work investigating the requirements
for functional miRNAs (53) shows that 50homology of 4–5 nt
betweenmiRNAanditstargetsiteissufﬁcienttofunctionasso
called ‘seed’ if it is accompanied by an extensive 30 homology
region following a central bulge. In addition, 50 seeds of 8 nt
homology are sufﬁcient even in the absence of 30 homology.
RNA oligo 2–5mers could therefore potentially compete with
the pairing between miRNA target and seed region of the
miRNA. In addition, the ability of short oligos to enter the
transcription bubble could be an alternative route of interfer-
ence with gene expression.
Essentiality of Orn in E.coli raised the possibility that this
downstream target of pAp could rescue the effects of pAp
accumulation observed in a cysQ mutant or in the wild type
under conditions of lithium treatment. We found this however
not to be the case. Although it is possible that due to the high
Figure 6. Sensitivity of Sfn to pAp. Shown is the quantification of the dis-
tributionofreactionproductsthatwereseparatedon22%PAAgels.Reactions
included 0.5 mg Sfn and and 3 mM of RNA oligo 5mer (50Cy5-CCCCC30).
Reactions were started by the addition of enzyme. pAp (20 or 50 mM) was
presentwhereindicated.Closedcircle,5mer;opencircle,4mer;closedtriangle,
3mer; open triangle, 2mer; square, 1mer.
Figure7.OrnisactiveonDNAoligos.Reactionscontained3mMofDNAoligo
5mer (50Cy5-CCCCC30) and were started by the addition of 1 mg of Orn. Dash
labels a control lacking enzyme incubated for 20 min. Samples were taken as
indicated.TheDNAmonomercannotenterthegel.Thedifferentgelmobilityas
compared with RNA is caused by the one missing charge of DNA. Varyingthe
pH of the electrophoresis buffer could not change this effect.
Nucleic Acids Research, 2006, Vol. 34, No. 8 2371sensitivity of Orn to pAp, overexpression might not be able to
overcome pAp-inhibition; an alternative explanation is the
existence of additional targets of pAp. Indeed, our search
for pAp targets is likely to be not exhaustive and restricted
to the ﬁnding of proteins with higher expression levels.
ThesecondhumanenzymewefoundtobindtopApisNDK.
The inhibition of NDK by 30-phosphorylated nucleotides, in
particular pAp and PAPS, was already reported (27); however,
our approach provides an independent conﬁrmation of the
physiological signiﬁcance of this inhibition. In addition to
maintenance of (d)NTP levels, NDKs were suggested to
have other important metabolic functions in processes such
as signal transduction (54) and developmental control (55).
In humans there exist eight different and widely expressed
NDKs, some of which play a critical role in development
(56–59). NDK A and NDK B are the most abundant and
closely related (88% identity) isoforms. The two NDK
homologs were shown to act as suppressors of tumor metas-
tasis but also to function in tumorogenesis, as reviewed in Ref.
(60,61). NDK B binds speciﬁcally to the promoter of the
c-myc oncogene and activates its transcription (62). This
activation involves structural rearrangements through cleav-
age of a nuclease hypersensitive region (63). Of interest for the
pAp-inhibitory effect is the fact that the residue required for
this cleavage reaction, Lys12, lies in the catalytic pocket
involved in the NDP kinase phosphorylation reaction (64).
pAp binds to NDK at the same site as the physiological sub-
strates (d)NTP or (d)NDP without disturbing the conformation
of the active site in an inverted position where the 30 phosphate
occupies the space the g-phosphate of ATP would reside in
(27) close to the catalytic histidine. ATP but not ADP was
shown to inhibit the cleavage reaction with 50% inhibition at
0.5 mM (65). Considering the fact that it is speciﬁcally the g-
phosphate and the adenine base that inhibits the cleavage and
not ATP hydrolysis or phosphorylation of the catalytic histi-
dine, we predict that pAp will inhibit not only NDP kinase
activity but also DNA cleavage required for transcription
activation of c-myc as well as repair (66). This is the more
likely as pAp makes polar interactions with Lys12 (27)
required for cleavage. A most interesting feature of this
remarkably conserved role is that it links sulfur metabolism
to completely unexpected targets. It is therefore of importance
to make an exhaustive analysis of pAp targets, as well as of
their evolution.
The knowledge of pAp targets can improve the molecular
understanding of the multifarious therapeutical and toxic
effects of lithium and might lead to more directed pharmaco-
logical approaches. Our ﬁndings suggest the existence of an
additional network of proteins, controlled by pAp levels, that
contributes signiﬁcantly in the mechanisms of lithium action
and is independent from the better explored GSK-3, and
protein kinase C networks (66).
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